Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.59 |
| ▸ | KDR | P35968 | 9/20 | 0.59 |
| ▸ | FLT1 | P17948 | 5/20 | 0.59 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.59 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.59 |
| ▸ | FLT4 | P35916 | 1/20 | 0.59 |
| ▸ | RET | P07949 | 1/20 | 0.58 |
| ▸ | KIF5B | P33176 | 1/20 | 0.58 |
| ▸ | EGFR | P00533 | 8/20 | 0.57 |
| ▸ | EPHA2 | P29317 | 5/20 | 0.57 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.57 |
| ▸ | EPHB4 | P54760 | 4/20 | 0.57 |
| ▸ | SRC | P12931 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16212241 | 0.92 | EGFR (0.63) | ABCG2KDRFLT1FGFR1EPHB2 | |
| SCHEMBL29719187 | 0.88 | EGFR (0.50) | ABCG2KDRFLT1FGFR1EPHB2 | |
| SCHEMBL157980 | 0.88 | EGFR (0.50) | ABCG2KDRFLT1FGFR1EPHB2 | |
| Hydrochloric Acid SCHEMBL17967496 | 0.87 | EGFR (0.49) | ABCG2KDRFLT1FGFR1EPHB2 | |
| SCHEMBL6669352 | 0.86 | KDR (0.77) | KDRFLT1FGFR1EPHB2FLT4 | |
| SCHEMBL29989073 | 0.86 | ABCG2 (0.65) | ABCG2KDRFLT1RETKIF5B | |
| SCHEMBL4778106 | 0.86 | ABCG2 (0.65) | ABCG2KDRFLT1RETKIF5B | |
| SCHEMBL28797709 | 0.85 | KDR (0.45) | ABCG2KDRFLT1FGFR1EPHB2 | |
| SCHEMBL19125433 | 0.85 | RAF1 (0.49) | ABCG2KDRFLT1FGFR1EPHB2 | |
| SCHEMBL29719183 | 0.85 | RAF1 (0.49) | ABCG2KDRFLT1FGFR1EPHB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180050993-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | TRILLIUM THERAPEUTICS INC. (CA) | 2018-02-22 | — | — | US | disclosed |
| US-20180050993-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | TRILLIUM THERAPEUTICS INC. (CA) | 2018-02-22 | — | — | US | disclosed |
| WO-2017117680-A1 | NOVEL FLUORINATED QUINAZOLINE DERIVATIVES AS EGFR INHIBITORS | TRILLIUM THERAPEUTICS INC. (CA) | 2017-07-13 | — | — | WO | disclosed |
| US-9556191-B2 | Aminoquinazoline derivatives and their salts and methods of use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-01-31 | — | — | US | disclosed |
| EP-2611797-B1 | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS | HANMI SCIENCE CO LTD (KR) | 2016-12-28 | — | — | EP | disclosed |
| WO-2016123706-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | TRILLIUM THERAPEUTICS INC. (CA) | 2016-08-11 | — | — | WO | disclosed |
| WO-2016123706-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | TRILLIUM THERAPEUTICS INC. (CA) | 2016-08-11 | — | — | WO | disclosed |
| US-20160039838-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-02-11 | — | — | US | disclosed |
| WO-2014177038-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-11-06 | — | — | WO | disclosed |
| US-8835458-B2 | Quinoline or quinazoline derivatives with apoptosis inducing activity on cells | HANMI SCIENCE CO., LTD (KR) | 2014-09-16 | — | — | US | disclosed |
| EP-2611797-A2 | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS | Hanmi Science Co., Ltd. (KR) | 2013-07-10 | — | — | EP | disclosed |
| US-20130165386-A1 | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS | HANMI SCIENCE CO., LTD (KR) | 2013-06-27 | — | — | US | disclosed |
| WO-2012030160-A2 | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS | HANMI HOLDINGS CO., LTD. (KR) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180050993-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | EGFR, ERBB2, ERBB4 | ABCG2 1286/4885KDR 339/4885FLT1 73/4885 |
| US-20160039838-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE THEREOF | WNK1, ABL1, NEK4 | ABCG2 828/4885KDR 1472/4885FLT1 694/4885 |
| US-20130165386-A1 | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS | CASP7, API5, BAX | ABCG2 2153/4885KDR 4712/4885FLT1 4447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.